Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)

Trial Profile

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapablursen (Primary)
  • Indications Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms IMPRSSION
  • Sponsors Ionis Pharmaceuticals

Most Recent Events

  • 08 Dec 2025 According to an Deciphera Pharmaceuticals media release, data from this trial were presented at the 67th American Society of Hematology (ASH) Annual Meeting.
  • 08 Dec 2025 Results presented in the Ono Pharmaceutical Media Release.
  • 06 Dec 2025 Primary endpoint has been met. (Change in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment Period)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top